RxDoctor Payments DataLook up a doctor →

Nicholas Thomson, MD

Hematology & Oncology · American Fork, UTNPI 1891106936

Payments from drug & device makers

$21,249in general payments, 2019–2025

Across 717 payments — averaging $29.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$7K
  • Novartis$2K
  • Incyte Corporation$1K
  • Pfizer$1K
  • AstraZeneca$980
  • Merck$719
  • plus $9K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Daiichi Sankyo Inc.35$6,735
Novartis68$1,515
Incyte Corporation22$1,279
Pfizer79$1,004
AstraZeneca(2 entities)51$980
Merck36$719
Astellas Pharma US Inc22$592
EMD Serono, Inc.26$589
Amgen27$534
Lilly USA, LLC20$517
Eisai Inc.29$502
E.r. Squibb & Sons, L.L.C.31$464
Seagen Inc.18$437
Johnson & Johnson18$407
Gilead(2 entities)18$372
Sanofi18$344
Bristol Myers Squibb14$298
Tersera Therapeutics LLC8$200
Bayer9$196
Pharmacyclics LLC, An Abbvie Company8$192
GSK10$187
Genentech USA, Inc.7$174
Dendreon Pharmaceuticals LLC6$165
AbbVie8$165
Array Biopharma Inc11$162
Sumitomo Pharma America, Inc.8$154
Genmab U.S., Inc.8$148
Regeneron Healthcare Solutions, Inc.6$135
Puma Biotechnology, Inc.6$128
Takeda Pharmaceuticals U.S.A., Inc.4$117
Pharmaessentia USA Corporation5$112
Sobi, Inc5$110
Taiho Oncology, Inc.2$81
Geron Corporation4$80
Coherus Oncology, Inc.3$80
Stemline Therapeutics Inc.3$79
Heron Therapeutics, Inc.4$77
Rigel Pharmaceuticals, Inc.3$75
Recordati_rare_diseases_inc.3$75
Kyowa Kirin, Inc.3$70
Karyopharm Therapeutics Inc.3$67
Agios Pharmaceuticals, Inc.3$62
Jazz Pharmaceuticals Inc.3$56
Pharmacosmos Therapeutics Inc.3$55
Mylan Institutional Inc.2$55
Deciphera Pharmaceuticals Inc.3$55
Epizyme, Inc.3$54
Foundation Medicine, Inc.3$52
Exelixis Inc.3$49
Pharming Healthcare, Inc.2$44
Azurity Pharmaceuticals, Inc.2$41
CTI Biopharma Corp.2$40
ADC Therapeutics America, Inc.2$34
Fennec Pharmaceuticals, Inc.2$32
Caris MPI, Inc.1$29
EUSA Pharma (US) LLC2$29
Amneal Pharmaceuticals LLC1$27
Myriad Genetic Laboratories, Inc.1$25
Servier Pharmaceuticals LLC1$23
Pharmaand GmbH1$23

How this compares

$21,249 in reported general payments places this provider in the 55th percentile of 77 hematology & oncology providers in Utah.

See all hematology & oncology providers in Utah →

Medicare billing

Part B allowed, 2024
$2,454,877
Medicare patients
284
Services billed
91,132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in American Fork

See the full list for Utah →

Where these figures come from

Is this you, or does something look wrong? →